Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
United European Gastroenterology Journal · 2024
DOI: 10.1002/ueg2.12524 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Hannes Hagström und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Syndrome. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MSD, The Swedish Cancer Society, Intercept Pharmaceuticals.
Abstract (Originalsprache)
Alcohol‐related liver disease (ALD) and non‐alcoholic fatty liver disease (NAFLD, recently renamed metabolic dysfunction‐associated steatotic liver disease [MASLD]) share many features, including certain pathophysiological mechanisms, susceptibility genes, and histological lesions. However, the natural history of the two diseases, studied separately, is significantly different, with ALD being associated with a higher risk of cirrhosis and liver‐related mortality. Moreover, evidence suggests an interactive effect between ALD and metabolic risk factors that are associated with NAFLD on the risk of progressive fibrosis and development of cirrhosis. Patients with both a high consumption of alcohol and metabolic risk factors, such as obesity or diabetes, should therefore be considered a particularly high‐risk group for cirrhosis. Additional studies regarding the efficacy of screening for advanced liver fibrosis or cirrhosis in these risk groups are needed. The most effective and established method for reducing the risk of progression in ALD is alcohol abstinence, whereas weight loss is effective in NAFLD. In this narrative review, we introduce the reader to the literature of the field and present key studies showing this interactive effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine, Karolinska Institute, Stockholm, Sweden.
- Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- Faculté de Médecine, Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.
ORCID-Profile: Hannes Hagström, Christophe Moreno
Förderung
- MSD
- The Swedish Cancer Society
- Intercept Pharmaceuticals
- Gilead Sciences
- Echosens
- The Swedish Research Council
- Radiumhemmet Research Foundation and Region Stockholm
- Pfizer
Zitieren
APA
Hagström, H., Hegmar, H., & Moreno, C. (2024). Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12524
Vancouver
Hagström H, Hegmar H, Moreno C. Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12524
BibTeX
@article{Hagstrm2024,
author = {Hagström, Hannes and Hegmar, Hannes and Moreno, Christophe},
title = {Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease},
journal = {United European Gastroenterology Journal},
year = {2024},
doi = {10.1002/ueg2.12524}
}
EUVIMED